Myriad Genetics Inc (MYGN)

15.66
0.20 1.29
NASDAQ : Services
Prev Close 15.46
Open 15.48
Day Low/High 15.36 / 15.74
52 Wk Low/High 28.82 / 46.24
Volume 1.54M
Avg Volume 1.25M
Exchange NASDAQ
Shares Outstanding 68.42M
Market Cap 1.08B
EPS 1.80
P/E Ratio 12.43
Div & Yield N.A. (N.A)

Latest News

EndoPredict® Reviewed By Blue Cross Blue Shield Association's Evidence Street

EndoPredict® Reviewed By Blue Cross Blue Shield Association's Evidence Street

The Level of Evidence for EndoPredict Consistent with that of First-Generation Test

Positive Clinical Utility Results Of Crescendo's Vectra® DA Test For Rheumatoid Arthritis Published In The Journal Arthritis & Rheumatology

Positive Clinical Utility Results Of Crescendo's Vectra® DA Test For Rheumatoid Arthritis Published In The Journal Arthritis & Rheumatology

Vectra DA Test Guides Treatment for Rheumatoid Arthritis Patients that are Methotrexate-Incomplete Responders

Myriad Genetics Will Present Results From Six Breast Cancer Studies At SABCS

Myriad Genetics Will Present Results From Six Breast Cancer Studies At SABCS

New Data on EndoPredict®, myRisk™ Hereditary Cancer and myChoice® HRD

Crescendo Bioscience Announces Four Studies With Vectra® DA Will Be Presented At The American College Of Rheumatology 2016 Annual Meeting

Crescendo Bioscience Announces Four Studies With Vectra® DA Will Be Presented At The American College Of Rheumatology 2016 Annual Meeting

Studies Advance the Knowledge of Vectra DA Utility for Clinicians and Patients with RA

Myriad Will Seek Japanese Regulatory Approval For BRACAnalysis CDx®

Myriad Will Seek Japanese Regulatory Approval For BRACAnalysis CDx®

Expands Its Companion Diagnostic Collaboration with AstraZeneca

The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings In Patients With Generalized Anxiety Disorder

The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings In Patients With Generalized Anxiety Disorder

New Data Will Be Presented at the NEI Psychopharmacology Congress

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AYR, CRCM, TG Downgrades: ADPT, AMZN, ANGI, ARNC, BKD, BWXT, CAJ, CALX, CSGP, EMR, HZO, LXRX, MNK, MYGN, NTRA, PBI, TCO, TRI Initiations: PFGC Read on to get TheStreet Quant Ratings' detailed report:

The Myriad MyPath® Melanoma Test Effectively Diagnosed Patients In The Largest Outcomes-Based Study For A Melanoma Diagnostic

The Myriad MyPath® Melanoma Test Effectively Diagnosed Patients In The Largest Outcomes-Based Study For A Melanoma Diagnostic

Data Being Presented at ASDP Demonstrate a Diagnostic Accuracy of >95 Percent

Myriad Genetics Teams Up With Project BioEYES To Advance STEM Education In Utah

Myriad Genetics Teams Up With Project BioEYES To Advance STEM Education In Utah

Employees Will Facilitate Classroom Learning and Inspire Students to Pursue Careers in Science

Rev's Forum: News Flow Works Against the Bears Once More

Rev's Forum: News Flow Works Against the Bears Once More

Those who thought we were ready to break down look foolish again.

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.

Myriad Announces Four Poster Presentations At The 2016 European Society For Medical Oncology (ESMO) Annual Meeting

Myriad Announces Four Poster Presentations At The 2016 European Society For Medical Oncology (ESMO) Annual Meeting

New Data Support the Utility of the Company's Advanced Companion Diagnostic Tests

Myriad Appoints Chip Parkinson As EVP For Reimbursement Strategy

Myriad Appoints Chip Parkinson As EVP For Reimbursement Strategy

Former Insurance Industry Executive Brings Significant Pharmaceutical, Diagnostic and Managed Markets Experience

Myriad To Present New MyRisk Hereditary Cancer Data Further Demonstrating The Benefits Of Gene Panel Testing

Myriad To Present New MyRisk Hereditary Cancer Data Further Demonstrating The Benefits Of Gene Panel Testing

Three Studies to Be Featured at the NSGC 35th Annual Education Conference

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

Here's a technical look at how to trade five stocks that are within range of triggering big breakout trades.